Following encouraging Phase 2a results, MMV will lead the next phase of cabamiquine's development.
Long-acting cabamiquine, with potential to become a single-dose treatment or prevention option, could help address drug resistance & block transmission: bit.ly/4ypoy9x
bit.ly
Promising long-acting malaria drug cabamiquine will move to next phase of development under MMV leadership | Medicines for Malaria Venture